Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nichi-Iko Gets Global Rights to Rituximab Biosimilar from S. Korea’s Aprogen
April 4, 2016
- Sakigake: Now and Future (5) - BioCryst’s BCX7353 Would Be Japan’s 1st Drug for Preventing Angioedema Attacks
April 4, 2016
- Daiichi Sankyo Files NDA for Hydromorphone, Standard Pain Therapy Outside Japan
April 1, 2016
- Towa Prevails in Patent Suit over Elplat
April 1, 2016
- Novartis to Sell 14 Long-Listed Brands to Sun Pharma in Japan, Likely to Stop Aredia Sales
April 1, 2016
- Daiichi Sankyo Eyes V-Shaped Recovery from Olmesartan Patent Cliff: 5-Year Plan
April 1, 2016
- Eisai Gives Rights for Cancer Drug to Dr. Reddy’s Outside Japan, Asia
April 1, 2016
- Gilead Files Japan NDA for Tenofovir Prodrug for Chronic Hep B
April 1, 2016
- Janssen Seeks MCL Indication for Imbruvica
April 1, 2016
- HPV Vaccine Makers, Govt to Face Class-Action Suit; MSD Says Plaintiffs’ Claim Unfounded
March 31, 2016
- Eisai Transfers Thrombocytopenia Drug to US Investment Firm
March 31, 2016
- Janssen Files Stelara for Crohn’s Disease
March 31, 2016
- EA Pharma to Start Up with 440 Sales Reps, Offer 24 Products
March 31, 2016
- Kyorin, Kissei to Jointly Develop, Market OAB Treatment
March 31, 2016
- Santen Gets Worldwide Rights to Ono’s FP and EP3 Dual Receptor Agonist
March 31, 2016
- Shionogi Files Japan, US NDAs for Naldemedine for Opioid-Induced Constipation
March 31, 2016
- Shionogi Says Complaint against ViiV-Related Tax Reassessment Rejected, Poised to Go to Court
March 30, 2016
- Astellas, Mitsubishi Tanabe to Share Compound Libraries
March 30, 2016
- In a Setback, FDA Rebuffs Label Expansion for Takeda’s Brintellix
March 30, 2016
- PeptiDream, Asahi Kasei Pharma Forge Research Collaboration
March 29, 2016
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…